Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: A multicentre retrospective study

By Manfredi A, Cassone G, Furini F, et al
Published September 15, 2020

Key Takeaways

Researchers undertook this national multicentre investigation to study the evolution of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patients managed with tocilizumab (TCZ). This study involved 28 RA‐ILD patients. At the end of follow up, forced vital capacity (FVC) was stable, improved, and worsened in 14 (56%), 5 (20%), and in 6 (24%) patients, respectively. Diffusing capacity of the lung for carbon monoxide (DLCO) remained stable in 14 (56%) patients, and it was improved and worsened in 5 (20%) and in 6 (24%) patients, respectively, even though an opposite trend was demonstrated by DLCO and FVC in 3 patients. Overall, experts inferred that management of RA‐ILD patients continues to be a critical unmet need. In addition to a good safety profile, TCZ was shown to have a potential impact on the stabilisation of lung involvement in patients with RA‐ILD.

Read the full article on Internal Medicine Journal.

Share with emailShare to FacebookShare to LinkedInShare to Twitter